Nektar and Bristol Myers Squibb Report Update on Phase 3 PIVOT IO-001 Trial
Mar 14, 2022 By MarketDepth
Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) have reported an update on the first analysis of the Phase 3 PIVOT IO-001 study that evaluates the doublet therapy of bempegaldesleukin with Opdivo compared to Opdivo monotherapy as a first line treatment for untreated unresectable or metastatic melanoma. Bristol Myers Squibb and Nektor were informed that the study did not meet its primary endpoints of progression free survival and objective response rate as assessed by Blinded Independent Central Review.
New Strategies for Treatment
“As a leader in developing innovative therapies for patients with cancer, we have continued to explore novel strategies that may expand treatment benefits to more patients with advanced disease,” said Jonathan Cheng, senior vice president and head of oncology development, Bristol Myers Squibb. “We are disappointed with the results of this trial, which we had hoped would lead to a new therapeutic option to treat metastatic melanoma. We express our gratitude to the patients, caregivers and investigators who chose to participate in these trials.” The other four studies ongoing for bempegaldesleukin plus Opdivo in renal cell carcinoma and bladder cancer are continuing.
“While we are surprised and deeply disappointed in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma and urothelial cancer, which are currently expected in the first half of 2022. We look forward to collaborating with BMS to evaluate the data from these other studies to guide the future development of bempegaldesleukin. Nektar remains dedicated to the development of therapeutics to treat cancer and auto-immune disease.”
Jonathan Zalevsky, chief research and development officer of Nektar Therapeutics
